Evidence map›Paper›PMID 40481086›Full record

ArticleScientific reports2025

Mathematical mechanistic model representing the cancer immunity cycle under radiation effects.

Taisuke Takayanagi, Koichi Miyazaki, Kana Yamasaki, Takahiro Yamada, Futaro Ebina, Takahiro Kanehira, Yasuhito Onodera, Keiji Kobashi, Hiroshi Taguchi, Koichi Yasuda and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Taisuke TakayanagiHitachi, Ltd. Research and Development Group, 2-1, Omika 7, Hitachi, Ibaraki, 319-1292, Japan.
Koichi MiyazakiHitachi, Ltd. Research and Development Group, 2-1, Omika 7, Hitachi, Ibaraki, 319-1292, Japan.
Kana YamasakiDivision of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, 606-8501, Japan.
Takahiro YamadaHitachi, Ltd. Research and Development Group, 2-1, Omika 7, Hitachi, Ibaraki, 319-1292, Japan.
Futaro EbinaHitachi, Ltd. Research and Development Group, 2-1, Omika 7, Hitachi, Ibaraki, 319-1292, Japan.
Takahiro KanehiraDepartment of Medical Physics, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan.
Yasuhito OnoderaGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Keiji KobashiDepartment of Medical Physics, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan.
Hiroshi TaguchiDepartment of Radiation Oncology, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan.
Koichi YasudaDepartment of Radiation Oncology, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Norio KatohDepartment of Radiation Oncology, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Takayuki HashimotoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Hidefumi AoyamaDepartment of Medical Physics, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan.
Hiroki ShiratoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Kenji ChamotoDivision of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, 606-8501, Japan. chamoto.kenji.4w@kyoto-u.ac.jp.

Funding

JSPS KAKENHI 19H03591
6 · The paper itself

Abstract

Combining radiotherapy with immune checkpoint inhibitors is a promising approach to improve the effectiveness of cancer treatment. However, the success rates of these clinical studies are limited. It is essential to determine the optimal irradiation scheme that maximizes the therapeutic effect by taking into account the balance between the positive and negative effects of radiation on immunity. In this context, we developed a mathematical mechanistic model that simulates (1) the balance between effector and exhausted cytotoxic T-lymphocytes (CTLs), (2) the number of neoantigens released by high-dose irradiation, and (3) the impact of radiation on draining lymph nodes (DLNs) for systemic anti-tumor immunity, and tested whether this mathematic model fits in several animal experiments. Our mechanistic model reproduced the anti-tumor effects of several cancer treatment models for combination therapies with radiation, immune checkpoint inhibitors, and/or a metabolic modulator. Furthermore, this mechanistic model simulated that tumor suppression in distant metastatic foci, known as the abscopal effect, was dysregulated by hypofractionated high-dose irradiation or by the direct radiation exposure on DLN. The mechanistic model successfully reproduced tumor control under various treatment conditions with appropriate parameters, indicating that it may be useful for optimizing immunoradiotherapy prescriptions.

Indexed as

Models, TheoreticalNeoplasmsAnimalsHumansImmune Checkpoint InhibitorsLymph NodesMiceT-Lymphocytes, CytotoxicImmune Checkpoint InhibitorsCancer-immune cycleDraining lymph nodeEffector and exhausted cytotoxic T-lymphocytesHypofractionationImmunoradiotherapyMechanistic model

Identifiers

PMID40481086
PMCPMC12144191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.